{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.","slug":"biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d","published_at":"2026-04-13T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/18988960-biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/18988960-biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we speak with Dr. Sarfaraz Niazi, Ph.D., about how biosimilar regulations have taken shape, from early FDA uncertainty to citizen petitions, lawsuits, and guideline changes. Dr. Niazi offers a behind the scene look at the way FDA policy gets made, and unmade, and his own role in key regulatory changes, and legislation such as the Biologics Price Competition and Innovations Act (BPCIA), a...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we speak with Dr. Sarfaraz Niazi, Ph.D., about h…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3513,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}